November 10, 2020
Penumbra Partners With RapidAI on Pulmonary Embolism Triage and Decision-Making
November 10, 2020—Penumbra, Inc. has announced a partnership with artificial intelligence company RapidAI aimed at enabling faster clinical decision-making for pulmonary embolism (PE) diagnosis and procedures.
Penumbra says the companies will work together to develop clinical and communications modules for PE with a goal of streamlining triage and decision-making by processing CT scans and delivering them to physicians. RapidAI will build on its experience in the field of neurointervention, where it has platforms addressing stroke, aneurysms, and intracranial hemorrhage. Penumbra recently launched the latest iteration of its Indigo line with Lightning Intelligent Aspiration.
“PE is at the precipice of a transformation in how patients affected by this condition are being treated. Several advances have been made during the last few years largely due to the PERT Consortium’s efforts, combined with innovation in therapeutic options,” commented Robert Lookstein, MD, in the companies’ announcement. Dr. Lookstein is President of the PERT Consortium, Professor of Radiology and Surgery at Icahn School of Medicine at Mount Sinai, and Executive Vice Chairman in the Department of Diagnostic, Molecular, and Interventional Radiology for the Mount Sinai Health System.
“This exciting new partnership will undoubtedly help bring more awareness to this very deadly disease. The entire field wants to rapidly bring more therapeutic options to a broader segment of the population. We collectively believe this will only improve outcomes.”